Zacks Investment Research upgraded shares of BIOLINERX Ltd/S (NASDAQ:BLRX) from a sell rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
A number of other equities research analysts have also recently weighed in on BLRX. HC Wainwright set a $4.00 price objective on shares of BIOLINERX Ltd/S and gave the company a buy rating in a research note on Tuesday, August 7th. ValuEngine upgraded shares of BIOLINERX Ltd/S from a hold rating to a buy rating in a research note on Tuesday, October 16th. MED started coverage on shares of BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They set a market perform rating on the stock. Finally, Maxim Group reiterated a buy rating and issued a $2.00 price target on shares of BIOLINERX Ltd/S in a research report on Monday, August 13th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of $2.50.
Shares of NASDAQ BLRX traded down $0.01 during midday trading on Wednesday, reaching $0.70. 391,694 shares of the company traded hands, compared to its average volume of 1,728,884. BIOLINERX Ltd/S has a 52 week low of $0.67 and a 52 week high of $1.84. The stock has a market cap of $78.77 million, a P/E ratio of -2.59 and a beta of 0.87.
BIOLINERX Ltd/S (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). Analysts expect that BIOLINERX Ltd/S will post -0.22 EPS for the current year.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new position in BIOLINERX Ltd/S (NASDAQ:BLRX) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned approximately 1.27% of BIOLINERX Ltd/S at the end of the most recent quarter. 34.69% of the stock is currently owned by hedge funds and other institutional investors.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
See Also: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.